Fig. 4From: An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancerPre-treatment immune pathway scores in patients with partial response (PR) and progressive disease (PD). a Antigen presentation score. b Cytokine and chemokine signaling score. c Immune infiltration scoreBack to article page